ArticleInternational journal of clinical and experimental medicine2015
Clinical value of microRNA-23a upregulation in non-small cell lung cancer.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- ETS1 promotes cisplatin resistance of NSCLC cells by promoting GRP78 transcription.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- MiREx: mRNA levels prediction from gene sequence and miRNA target knowledge.BMC bioinformatics · 2023Article
- Small RNA Deep Sequencing of Circulating Small RNAs Discovers a Unique Panel of microRNAs as Feasible and Reliable Biomarkers of Non-Small Cell Lung Cancers in Northern Thailand.Asian Pacific journal of cancer prevention : APJCP · 2023Review
- The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer.Molecular therapy oncolytics · 2022Article
- Long non-coding RNA ZNF674-AS1 regulates miR-23a/E-cadherin axis to suppress the migration and invasion of non-small cell lung cancer cells.Translational cancer research · 2021Article
- Serum Extracellular Vesicle-Derived miRNAs in Patients with Non-Small Cell Lung Cancer-Search for Non-Invasive Diagnostic Biomarkers.Diagnostics (Basel, Switzerland) · 2021Article
- Expression of miR-23a and miR-135 and tumor markers in gastric cancer patients and the significance in diagnosis.Oncology letters · 2019Article
- [Plasma miRNA-23a and miRNA-451 as candidate biomarkers for early diagnosis of nonsmall cell lung cancer: a case-control study].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- Article
- Review
- MicroRNA-23a/24-2/27a as a potential diagnostic biomarker for cancer: A systematic review and meta-analysis.Molecular and clinical oncology · 2018Article
- Upregulated expression of miR-421 is associated with poor prognosis in non-small-cell lung cancer.Cancer management and research · 2018Article
- Disease relevant modifications of the methylome and transcriptome by particulate matter (PMEpigenetics · 2017Article
- Long Noncoding RNA GAS5 Suppresses Tumorigenesis by Inhibiting miR-23a Expression in Non-Small Cell Lung Cancer.Oncology research · 2017Article
- The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53.Frontiers in physiology · 2017Article
- Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.Cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMiR-23a function as an oncogene in several human cancers, however, its clinical value has not been investigated in NSCLC.
methodsTissue samples were obtained from 127 NSCLC patients who underwent complete resection at Yantaishan Hospital from March 2008 to January 2014. The expression level of miR-23a was detected in NSCLC tissues and the matched adjacent lung tissues by qRT-PCR. The survival analysis was estimated by the Kaplan-Meier method and was compared by using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model.
resultsThe expression level of miR-23a was significantly up-regulated in NSCLC tissues compared with matched adjacent lung tissues (P<0.001). The expression of miR-23a in NSCLC tissues was significantly associated with the smoking status (P=0.001), tumor size (P=0.002), lymphnode metastasis (P<0.001), TNM stage (P=0.001), and tumor differentiation (P=0.004). The overall survival was significantly lower in patients with higher miR-23a expression than in patients with lower miR-23a expression (P=0.02). In addition, multivariate analysis demonstrated that high miR-23a expression (HR=3.558, 95% CI: 2.982-6.635, P=0.011) was significant prognostic factor for NSCLC patients.
conclusionsmiR-23a might play an oncogenic role in NSCLC and is a poor prognostic factor. Our results must be verified by large-scale prospective studies with standardized methodology.
Indexed as
Identifiers
26550300PMC4612985W2173696638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.